etoposide has been researched along with Ovarian Diseases in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Huang, YH; Xin, XY; Zhang, QH; Zhao, XJ | 1 |
Müller, U; Stahel, RA | 1 |
Bauer, H; Fehrentz, D; Hunstein, W; Keilholz, U; Körbling, M | 1 |
3 other study(ies) available for etoposide and Ovarian Diseases
Article | Year |
---|---|
The GnRH antagonist reduces chemotherapy-induced ovarian damage in rats by suppressing the apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cyclophosphamide; Etoposide; Female; Gonadotropin-Releasing Hormone; Immunohistochemistry; Ovarian Diseases; Ovarian Follicle; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Rats; Rats, Sprague-Dawley | 2009 |
Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Ovarian Diseases; Prednisone; Retrospective Studies; Testicular Diseases; Vincristine | 1993 |
Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Endocrine System Diseases; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Libido; Lymphoma; Male; Menstruation Disturbances; Middle Aged; Ovarian Diseases; Whole-Body Irradiation | 1989 |